EBS Q3 2022 Earnings — Emergent BioSolutions Inc. Revenue & Financial Results | Market Cap Arena

EBSEmergent BioSolutions Inc.

$446M

Q3 2022 Earnings

Healthcare Drug Manufacturers - Specialty & Generic

Income Statement

Revenue

$240M-27.1% YoY

Gross Profit

$51M21.3% margin

Operating Income

-$45M-18.9% margin

Net Income

-$87M-36.3% margin

EPS (Diluted)

$-1.52

QoQ Revenue Growth

+0.0%

Cash Flow

Operating Cash Flow

-$74M

Free Cash Flow

-$102M

Stock-Based Comp.

$11M

Balance Sheet

Total Assets

$2.9B

Total Liabilities

$1.5B

Stockholders' Equity

$1.4B

Cash & Equivalents

$241M

Year-over-Year Comparison

Metric	Current	Year Ago	Change
Revenue	$240M	$329M	-27.1%
Gross Profit	$51M	$63M	-18.6%
Operating Income	-$45M	-$35M	-30.5%
Net Income	-$87M	-$33M	-166.4%

Revenue Segments

Product

$186M78%

Contract Development And Manufacturing

$36M15%

Contracts and Grants

$17M7%

Geographic Segments

Non-US

$190M79%

UNITED STATES

$50M21%